TriGemX Bio closes a $94 million financing round co-led by The Column Group, TCGX, and Viking Global Investors to advance phase 3 trials for their migraine treatment elismetrep.
PRIVATEOct 01, 2026
Amount Raised
$94 Million
Round Type
Venture
New YorkBiotechnologyHealth Care
Investors
Viking Global InvestorsTcgxThe Column Group
Description
TriGemX Bio, a biotechnology company focused on migraine treatments, has announced the closing of a $94 million financing. The funding will support the clinical development of elismetrep, their lead program. The round was co-led by The Column Group, TCGX, and Viking Global Investors, with additional participation. This financing marks a significant step toward advancing their innovative treatment.
Company Information
Company
TriGemX Bio
Location
New York, New York, United States
About
TriGemX Bio is a biotechnology company focused on developing a first-in-class medicine for the treatment of migraine. They are advancing the clinical development of their lead program, elismetrep, which is a novel, oral TRPM8 channel blocker.
Fundz sees it the moment TriGemX Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
New YorkBiotechnologyHealth Care